INVITRO EFFICACY OF TRANSFERRIN-TOXIN CONJUGATES AGAINST GLIOBLASTOMA-MULTIFORME

被引:42
作者
HALL, WA
GODAL, A
JUELL, S
FODSTAD, O
机构
[1] UNIV MINNESOTA HOSP & CLIN, DEPT NEUROSURG, MINNEAPOLIS, MN 55455 USA
[2] NORWEGIAN RADIUM HOSP, INST CANC RES, DEPT TUMOR BIOL, OSLO 3, NORWAY
[3] HAFSLUND NYCOMED AS, OSLO, NORWAY
关键词
BRAIN NEOPLASM; BRAIN-NEOPLASM ANTIGEN; IMMUNOTOXIN; TRANSFERRIN RECEPTOR;
D O I
10.3171/jns.1992.76.5.0838
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The cytotoxic activity of immunotoxins constructed with human diferric transferrin (Tfn) as the carrier ligand and an abrin variant Pseudomonas exotoxin A (PE) and the diphtheria toxin material (CRM) 107 as the toxin moieties were studied in vitro. Three malignant human cell lines, the glioblastomas multiforme SNB19 and SF295 and the LOX melanoma, and a nonhuman control murine melanoma cell line B16 were assessed. The presence of transferrin receptors on the cell lines was confirmed by direct I-125-Tfn binding assays. The 50% protein synthesis inhibitory concentration (IC50) values for all cell lines demonstrated that Tfn-abrin variant and Tfn-PE had comparable potency and were both more effective than Tfn-CRM 107. Monensin, a carboxylic ionophore, potentiated the effect of Tfn-abrin variant against glioma cells approximately 35-fold with IC50 values of 4.0 X 10-13 M and 4.7 x 10-12 M for SNB19 and SF295. respectively. Cytotoxic activity of Tfn-abrin variant (with or without monensin) and Tfn-PE was correlated with the degree of Tfn receptor expression measured on the cell lines. The exquisite in vitro cytotoxicity of Tfn-abrin variant and Tfn-PE immunotoxins against glioma and melanoma cells warrants further in vivo evaluation and future consideration of these agents for potential clinical application against glioblastoma multiforme and leptomeningeal neoplasia.
引用
收藏
页码:838 / 844
页数:7
相关论文
共 69 条
[1]  
AKIYAMA S, 1985, CANCER RES, V45, P1005
[2]   INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].
BARBA, D ;
SARIS, SC ;
HOLDER, C ;
ROSENBERG, SA ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182
[3]   BIOLOGY OF GLIOMAS - POTENTIAL CLINICAL IMPLICATIONS OF GLIOMA CELLULAR HETEROGENEITY [J].
BIGNER, DD .
NEUROSURGERY, 1981, 9 (03) :320-326
[4]   IMMUNOTOXINS - HYBRID MOLECULES OF MONOCLONAL-ANTIBODIES AND A TOXIN SUBUNIT SPECIFICALLY KILL TUMOR-CELLS [J].
BLYTHMAN, HE ;
CASELLAS, P ;
GROS, O ;
GROS, P ;
JANSEN, FK ;
PAOLUCCI, F ;
PAU, B ;
VIDAL, H .
NATURE, 1981, 290 (5802) :145-146
[5]  
BREGA K, 1990, CANCER, V66, P2105, DOI 10.1002/1097-0142(19901115)66:10<2105::AID-CNCR2820661011>3.0.CO
[6]  
2-I
[7]   APPLICATIONS OF MONOCLONAL-ANTIBODIES IN THE DIAGNOSIS AND TREATMENT OF PRIMARY BRAIN-TUMORS [J].
BULLARD, DE ;
BIGNER, DD .
JOURNAL OF NEUROSURGERY, 1985, 63 (01) :2-16
[8]  
CAPONE PM, 1984, J NATL CANCER I, V72, P673
[9]  
CASELLAS P, 1984, J BIOL CHEM, V259, P9359
[10]   SENSITIVITY OF HUMAN GLIOMA-CELLS TO CYTO-TOXIC HETEROCONJUGATES [J].
COLOMBATTI, M ;
BISCONTI, M ;
DELLARCIPRETE, L ;
GEROSA, MA ;
TRIDENTE, G .
INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (03) :441-448